Introduction
============

Hidradenitis Suppurativa (HS) is a chronic inflammatory disease, the exact pathophysiology of which remains poorly defined ^[@ref-1]^. Dysregulation of the T ~h~17: Treg axis ^[@ref-2]^, IL-36 signalling pathways ^[@ref-3]^ and keratinocyte-mediated inflammatory cytokines ^[@ref-4]^ have been demonstrated in lesional skin, blood, serum, and exudate ^[@ref-5]--\ [@ref-8]^ although contradictory results exist ^[@ref-4],\ [@ref-9]^. Given the variable and incomplete response of patients to treatment, including monoclonal antibodies ^[@ref-1]^, some authors have proposed clinical ^[@ref-10],\ [@ref-11]^, and immunological ^[@ref-5]^ subtypes of HS in an effort to better predict treatment outcome and response. Thus far, no current schema accurately predicts treatment efficacy.

In order to develop and implement effective treatment strategies in HS, a deeper understanding of the underlying inflammatory pathophysiology is needed. However, due to the heterogeneity of sampling methods, laboratory processing methods and data analysis, comparison across studies is problematic and potentially biased or inaccruate ^[@ref-12]^. Heterogeneity of tissue sampling and laboratory techniques alone may explain the inconsistent and conflicting results regarding specific cytokines, ^[@ref-4],\ [@ref-9]^ however, no systematic analysis of cytokine studies has been undertaken to compare results, methodology, and analytical techniques.

An additional complicating factor is that clinical comorbidities, which are strongly associated with disease activity in HS, such as obesity ^[@ref-13]^, diabetes ^[@ref-14]^, inflammatory bowel disease ^[@ref-15]^, and smoking ^[@ref-16]^, also produce pro-inflammatory cytokines, which affect multiple organ systems including the skin ^[@ref-15],\ [@ref-17]--\ [@ref-19]^. Hence, it remains unclear whether the presence or absence of these conditions confound the findings of cytokine studies in HS, and whether clinical stratification of patients is necessary to identify significant pathogenic pathways, which may be amenable to pharmacological intervention. Critical evaluation and analysis of existing studies may also enable meta-analysis, which may identify cytokines, which, in smaller studies, do not have sufficient power to meet statistical significance when compared to controls.

Objectives
==========

The objectives of this systematic review are:

1.  To collate and describe all published reports of human cytokine studies in HS including those in skin, blood, serum and exudate.

2.  To critically evaluate the sampling, laboratory and analysis techniques used in each study to assess whether comparisons can be made across individual studies.

3.  To analyze the heterogeneity of published studies enable meta-analysis

Methods
=======

This systematic review was registered with PROSPERO ^[@ref-20]^ (Registration number [CRD42018104664](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=104664)) and was conducted in line with the PRISMA checklist ^[@ref-21]^

Data sources
------------

Information sources for this review included [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/) (1946-July 1 2018), [Scopus](https://www.scopus.com/search/form.uri?display=basic) (2004- July 1 2018) and [Web of Science](http://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=F475qxcxjyk5hlPqeIw&preferencesSaved=) (1990-July 1 2018) as shown in [Figure 1](#f1){ref-type="fig"}. Search strategy is presented in [Table 1](#T1){ref-type="table"}

![PRISMA Flowchart.](f1000research-7-18879-g0000){#f1}

###### Search Strategy.

  ----------------------------------------------------------------------------------------------------------------------------------
  Resources:                
  ------------------------- --------------------------------------------------------------------------------------------------------
                            1)   Pubmed (1946-July 1 2018),\
                            2)   Scopus (2004- July 1 2018)\
                            3)   Web of Science (1990-July 1 2018)\
                            4)   Published Abstracts\
                            5)   Contact with Authors for abstracts without full text for clarification of data and methodology

  Pubmed Search Strategy:   

                            acne inversa OR apocrine acne OR apocrinitis OR Fox-den disease OR hidradenitis axillaris OR HS OR\
                            pyodermia sinifica fistulans OR Velpeau's disease OR Verneuil's disease OR Hidradenitidis Suppurative\
                            AND\
                            Cytokine OR chemokine OR inflammatory mediator
  ----------------------------------------------------------------------------------------------------------------------------------

Study eligibility criteria
--------------------------

Eligibility criteria for this review included cohort studies, case-control studies and other observational studies with no restrictions of patient age, sex, ethnicity or language of publication. Eligible studies included:

1.  Studies reporting the results of cytokine investigations (in cutaneous tissue, serum, blood or exudate) in human subjects clinically diagnosed with hidradenitis suppurativa.

Studies deemed not eligible included those which:

1.  Provide no new data but a review or summary of previously published data

2.  Provide no comparison with controls or non-lesional tissue

Appraisal and synthesis methods
-------------------------------

Data collection was performed independently by 2 authors (JWF & JEH), with any disagreements regarding inclusion of citations being referred to a third author (JGK) for mediation. Information was collected using a standardized data collection form (available as Extended data ^[@ref-22]^) with the principal outcomes of interest being the cytokine of interest, measured level of cytokine in lesional HS skin or serum. Comparison data against either peri-lesional, unaffected or control skin or serum was also collated. If data from individual patients was not available then the aggregate data including average change and statistical analyses of the significance of change was collected.

For each individual cytokine, where more than one study reported results, heterogeneity was assessed using the chi-squared tests for homogeneity. Homogeneity was defined as a chi squared value \>0.05. All statistical analysis was undertaken using [R](https://www.r-project.org/) (version 3.5.1)

Potential sources of bias in the identified studies are acknowledged including the small size of patient cohorts, the variability in sampling, laboratory techniques and the inclusion of patients being treated with a wide-variety of medications including immunosuppressants. Bias was also assessed using the NIH quality assessment tool for observational studies ^[@ref-23]^.

Results
=======

A total of 367 non-duplicated citations were identified in the literature review ( [Figure 1](#f1){ref-type="fig"}). 343 of these articles were removed upon review of titles and abstracts against the pre-defined eligibility criteria. Full text review of the remaining 24 articles excluded 5 review articles providing no new data. The remaining 19 studies ^[@ref-2]--\ [@ref-9],\ [@ref-24]--\ [@ref-33]^ included the results of 564 individual HS patients and 198 control patients, which were included in this systematic review.

Demographics
------------

The summarized demographic data of the patients and controls comprising this review are included in [Table 2](#T2){ref-type="table"}. The 564 reported cases comprised of 231 males (40.9% reported cases) and 333 females (59.0%). 24 cases were unreported (4.1%). The average age was 38.5 years (n=560, 18 cases unreported). 141 individuals were current smokers (82.4% reported cases), 8 ex-smokers (4.7% reported cases), 22 non-smokers (12.8% reported cases) and 407 unreported. Obesity (BMI\>30) was reported in 85 individuals (42.5% reported cases), with 115 (57.5%) individuals non-obese (BMI\<30) and unreported in 378 cases. 8 cases reported diabetes mellitus out of 24 reports (33% of reported cases). 12/38 cases reported a positive family history of HS (31.6% reported cases). Hurley Stage was reported as stage 1 in 68 individuals (17.4% reported), stage 2 in 199 individuals (51% reported cases) and stage 3 in 123 individuals (31.6% reported cases) with 188 cases going unreported. The average mHSS (modified hidradenitis suppurativa score) was 78.1 (n=247 cases). Biopsies were largely taken from the axillae (n=32, 43.8%) and groin (n=35, 48.0%), with a minority of samples being taken from the genital and perianal region (n=6, 8.2%). At the time of sampling patients were on treatment including Clindamycin+ Rifampicin (n=18); adalimumab (n=26); Metformin (n=2); levothyroxine (n=1); MABp1 (n=10); tetracyclines (n=12) Infliximab (n=2); other antibiotics (n=4). Treatment was not specified in 74 cases, with no treatment in 86 individuals and treatment withheld in 85 patients.

###### Demographic data of included studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Number\          Male         Female   Mean Age (Years)      Comorbidities   Biopsy Sites   Hurley\     mHSS Score (Mean)   Therapy                Study\                                                                                                                         
  of HS\                                                                                      Staging                                                Reference                                                                                                                      
  Patients                                                                                                                                                                                                                                                                          
  ---------------- ------------ -------- --------------------- --------------- -------------- ----------- ------------------- ---------------------- ------------------------- --------------------- -------------------------- ------------------------- ------------------------- -----------
  17                            1        45                    Ex              Y              NR          NR                  Serum Measurements     2                         NR                    Thyroxine                  [@ref-2]                                            

                   1            39       Y                     N               NR             NR          2                   NR                     N                                                                                                                              

                   1            24       N                     N               NR             NR          2                   NR                     N                                                                                                                              

                   1            41       Y                     Y               NR             NR          2                   NR                     N                                                                                                                              

                   1            23       Ex                    Y               NR             NR          1                   NR                     N                                                                                                                              

                   1            35       Y                     Y               NR             NR          2                   NR                     N                                                                                                                              

                   1            30       Y                     N               NR             NR          2                   NR                     Metformin                                                                                                                      

                   1            41       Y                     Y               NR             NR          3                   NR                     Clindamycin, Rifampicin                                                                                                        

                   1            35       Y                     Y               NR             NR          3                   NR                     Metformin                                                                                                                      

                   1            47       Y                     N               NR             NR          3                   NR                     N                                                                                                                              

  1                             19       N                     N               NR             NR          1                   NR                     N                                                                                                                              

  1                             34       Y                     N               NR             NR          2                   NR                     Adalimumab                                                                                                                     

                   1            47       N                     N               NR             NR          3                   NR                     Adalimumab, Doxycycline                                                                                                        

                   1            32       Y                     N               NR             NR          2                   NR                     Adalimumab                                                                                                                     

                   1            38       Y                     N               NR             NR          3                   NR                     Adalimumab, Doxycycline                                                                                                        

                   1            24       Y                     Y               NR             NR          2                   NR                     Adalimumab                                                                                                                     

                   1            26       E                     Y               NR             NR          2                   NR                     Adalimumab                                                                                                                     

  18               11           7        (Range 19--62)        NR              NR             NR          NR                  NR                     NR                        NR                    [@ref-24]                                                                      

  15               6            9        38.7                  NR              NR             NR          NR                  N=9                    N=4                       N=2                   Stage 1=0\                                           N                         [@ref-3]
                                                                                                                                                                                                     Stage 2=10\                                                                    
                                                                                                                                                                                                     Stage 3=5                                                                      

  18               1            1        38                    N               Y              NR          N                   NR                     NR                        NR                    3                          54                        N                         [@ref-4]

  1                             42       Y                     N               NR             N           NR                  NR                     NR                        3                     56                         N                                                   

  1                             30       N                     Y               NR             Y           NR                  NR                     NR                        3                     57                         Tetracycline                                        

                   1            43       Y                     N               NR             N           NR                  NR                     NR                        1                     11                         Tetracycline                                        

                   1            32       N                     Y               NR             Y           NR                  NR                     NR                        1                     14                         Tetracycline                                        

                   1            14       N                     N               NR             N           NR                  NR                     NR                        3                     65                         Rifampicin, Clindamycin                             

                   1            47       Y                     N               NR             N           NR                  NR                     NR                        3                     44                         Tetracycline                                        

                   1            43       Y                     Y               NR             N           NR                  NR                     NR                        3                     22                         N                                                   

                   1            21       Y                     N               NR             N           NR                  NR                     NR                        1                     13                         Tetracycline                                        

                   1            47       N                     N               NR             N           NR                  NR                     NR                        1                     11                         Tetracycline                                        

                   1            27       Y                     N               NR             N           NR                  NR                     NR                        2                     7                          Tetracycline                                        

                   1            22       N                     N               NR             Y           NR                  NR                     NR                        3                     68                         N                                                   

  1                             50       Y                     N               NR             Y           NR                  NR                     NR                        2                     46                         N                                                   

                   1            23       N                     N               NR             Y           NR                  NR                     NR                        2                     22                         N                                                   

                   1            19       Y                     Y               NR             N           NR                  NR                     NR                        2                     26                         N                                                   

                   1            44       Y                     N               NR             Y           NR                  NR                     NR                        2                     14                         N                                                   

  1                             22       Y                     N               NR             N           NR                  NR                     NR                        3                     23                         N                                                   

                   1            20       N                     N               NR             Y           NR                  NR                     NR                        2                     21                         Tetracycline                                        

                   1            48       Y                     N               NR             N                               1                                                3                     NR                         Rifampicin, Clindamycin                             

  1                             25       Y                     N               NR             N           1                                                                    2                     NR                         Amoxicillin+ Clav Acid                              

                   1            20       N                     N               NR             N           1                                                                    2                     NR                         N                                                   

                   1            31       N                     Y               NR             N                                                      1                         3                     NR                         Adalimumab                                          

  1                             40       NA                    NA              NR             NA                                                                               3                     NR                         N                                                   

                   1            46       Y                     N               NR             N                                                      1                         3                     NR                         Tetracycline                                        

                   1            26       Y                     N               NR             N           1                                                                    2                     NR                         Azithromycin                                        

                   1            36       Y                     N               NR             N                               1                                                2                     NR                         Amoxicillin+ Clav Acid                              

                   1            29       N                     N               NR             y                                                      1                         2                     NR                         Amoxicillin+ Clav Acid                              

  24               8            16       36.5 (Range 21--51)   NR              NR             NR          NR                  NR                     NR                        NR                    Mean=2.29\                 NR                        Untreated                 [@ref-7]
                                                                                                                                                                                                     (SD=0.62)                                                                      

  74               36           38       37.4 (SD=12.0)        NR              N=32\          NR          NR                  Serum Measurements     Stage 1= 11\                                    All on treatment\          [@ref-8]                                            
                                                                               (43.2%)                                                               Stage 2=47\                                     (Not further elaborated)                                                       
                                                                                                                                                     Stage 3=16                                                                                                                     

  8                4            4        41.61 (SD=13.81)      N=5\            NR             N=4         NR                  Exudate Measurements   Stage 1=0\                68.88 (SD=41.45)      NR                         [@ref-6]                                            
                                                               Y=2\                                                                                  Stage 2=3\                                                                                                                     
                                                               Ex=1                                                                                  Stage 3=5                                                                                                                      

  19\              11           8        45.6 (SD=10.7)        N=14\           N=13\          NR          NR                  Serum Measurements     Stage 1=0\                82.79 (SD 41.0)       NR                         [@ref-25]                                           
  19                                                           (74%)           (68.4%)                                                               Stage 2=9\                                                                                                                     
                                                                                                                                                     Stage 3=10                                                                                                                     

  34.5 (SD 43.5)   Adalimumab                                                                                                                                                                                                                                                       

  120              43           77       37.3 (SD=5.9)         NR              NR             NR          NR                  Serum Measurements     Stage 1=39\               28.1 (SD=20.2)\       NR                         [@ref-5]                                            
                                                                                                                                                     Stage2=52.4\              52.4 (SD=24.9)\                                                                                      
                                                                                                                                                     Stage 3=44                129.3 (SD=79.2)                                                                                      

  44               13           31       39.1 (SD=11.4)        Y=34\           N=16           NR          NR                  NR                     NR                        NR                    Stage 1=5\                 NR                        N=15 Rifampicin,\         [@ref-31]
                                                               Ex=4                                                                                                                                  Stage 2=27\                                          Clindamycin\              
                                                                                                                                                                                                     Stage 3=12                                           N=1 Minocycline N=2\      
                                                                                                                                                                                                                                                          Adalimumab\               
                                                                                                                                                                                                                                                          n=2 Infliximanb n=24\     
                                                                                                                                                                                                                                                          untreated                 

  22               10           12       38.2 (Range 19-60)    NR              NR             NR          NR                  NR                     NR                        NR                    NR                         NR                        NR                        [@ref-30]

  3                             1        54                    NR              NR             NR          NR                  NR                     NR                        NR                    NR                         NR                        NR                        [@ref-9]

  1                             36       NR                    NR              NR             NR          NR                  NR                     NR                        NR                    NR                         NR                                                  

                   1            59       NR                    NR              NR             NR          NR                  NR                     NR                        NR                    NR                         NR                                                  

  10               5            5        42 (Range 21--49)     NR              NR             NR          NR                  1                      1                         N                     Stage 2\                   NR                        Treatment Withheld        [@ref-32]
                                                                                                                                                                                                     (100%)                                                                         

  20               8            12       37.5 (Range 21--51)   N=18            N=10           NR          NR                  NR                     NR                        NR                    NR                         NR                        Treatment Withheld\       [@ref-29]
                                                                                                                                                                                                                                                          (8 weeks prior)           

  25               9            16       36 (Range 18--51)     NR              NR             NR          NR                  NR                     NR                        NR                    Mean =2.16\                NR                        Treatment Withheld\       [@ref-28]
                                                                                                                                                                                                     (SD=0.55)                                            (3 weeks prior)           

  47               19           28       42.3 (Range 22--54)   NR                                                             Serum Measurements                               48.3 (Range 8--144)   NR                         [@ref-27]                                           

  11               9            2        39.6 (Range 18--61)   NR              NR             NR          NR                  NR                     NR                        NR                    "Mod-Severe\               NR                        NR                        
                                                                                                                                                                                                     Disease"                                                                       

  20               6            14       40 (SD=15)            19              27.6 (4.1)     NR          NR                  7                      12                        1                     Stage 1=4\                                           Treatment withheld\       [@ref-26]
                                                                                                                                                                                                     Stage 2=11\                                          3 weeks prior             
                                                                                                                                                                                                     Stage 3=5                                                                      

  10               1            9        38 (SD=15)            10              28.9 (SD\      NR          NR                  3                      7                         0                     Stage1=2\                                            Treatment Withheld\       
                                                                               4.5)                                                                                                                  Stage2=7\                                            3 weeks prior             
                                                                                                                                                                                                     Stage3=1                                                                       

  10               7            3        46.6 (SD=15.1)        10              29.4 (4.7)     3           2                   Serum                  Stage 3=10                195.6 (SD=97.9)       MABp1                      [@ref-33]                                           

  10               6            4        49.3 (SD=9.8)         8               27.9 (7.1)     1           2                   Stage 2=2\             124.9 (SD=73.7)           No Treatment                                                                                         
                                                                                                                              Stage 3=8                                                                                                                                             

  TOTAL:\          231          333      38.5                  141             85 (0f 200)    8 (of 24)   12                  32                     35                        6                     Stage 1= 68\               Average =78.1\            Clindamycin+\             
  564                                                                                                                                                                                                Stage 2=199\               (n=247)                   Rifampicin=18;\           
                                                                                                                                                                                                     Stage 3=123                                          Adalimumab=26;\           
                                                                                                                                                                                                                                                          Metformin=2; Treatment\   
                                                                                                                                                                                                                                                          withheld= 85;\            
                                                                                                                                                                                                                                                          Thyroxine=1; MABp1=10;\   
                                                                                                                                                                                                                                                          Tetracycylines=12;\       
                                                                                                                                                                                                                                                          No Treatment=86;\         
                                                                                                                                                                                                                                                          Not Specified=74;\        
                                                                                                                                                                                                                                                          Infliximab=2;\            
                                                                                                                                                                                                                                                          Antibiotics=4; Not\       
                                                                                                                                                                                                                                                          Reported=258              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI= Body Mass Index mHSS= modified Hidradenitis Suppurativa Score (Sartorius Score) NR= Not Reported SD= Standard Deviation Y= Yes N=No Ex= Ex Smoker

Only 5/19 (26.3%) studies analysed both lesional tissue and serum levels of cytokines, enabling direct comparison between these two compartments. 8/19 (42.1%) studies provided age and sex matched controls, 5/15 (33.3%) studies stratified by disease severity and no studies stratified by lesion site or comorbidities. 8/19 (42.1%) studies stratified or accounted for treatment or reported discontinuing treatment up to 3 weeks prior to sample collection ( [Table 3](#T3){ref-type="table"}).

###### Critical evaluation of methodology of studies included in this review.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytokines Measured                          Number\    Number of\   Samples\      Age/Sex\   Timing of\   Stratified\   Stratified\   Stratified\   Stratified by\          Sample\    Sample Types    Study\
                                              of HS\     Controls     Analyzed      Matched\   Samples      by\           by lesion\    by Co-\       Treatment               Storage\                   Reference
                                              Patients                              Controls                severity      site          morbidities                           Time                       
  ------------------------------------------- ---------- ------------ ------------- ---------- ------------ ------------- ------------- ------------- ----------------------- ---------- --------------- -----------
  IL-17 IL-22 IFNg IL-2 IL-10 GM-CSF          17         9            L, PL, U,\    Y          NR           NR            N             N             Y                       NR         Skin, Serum     [@ref-2]
                                                                      C, S                                                                                                                               

  S100A7 Lysozyme LL37 hBD3 α-MSH\            18         12           L             N          NR           NR            N             N             N                       NR         Skin            [@ref-24]
  MIF TNF-α IL-8 MHC1                                                                                                                                                                                    

  IL-36α IL-36β IL-36g                        15         15           L, PL         NR         NR           NR            N             N             N                       NR         Skin            [@ref-3]

  IL-17 IL-22 IFNg CCl20 CCL27\               18         18           L, PL, S      Y          NR           Y             N             N             N                       NR         Skin, Serum     [@ref-4]
  S100A7 S100A8 IL-1B CCL5 IP10 IL-8\                                                                                                                                                                    
  IL-6 TNF-α                                                                                                                                                                                             

  LL37 IL-17 TNF-α IL-23 IL-1b IL-10\         24         9            L             Y          NR           NR            NR            N             Y (untreated)           NR         Skin            [@ref-7]
  IL-32                                                                                                                                                                                                  

  IL-6 IL-23 TNF-α R1 IL-1β IL-8 IL-10\       74         22           Serum only    N          NR           Y             NR            N             N                       NR         Serum           [@ref-8]
  IL-12p70 IL17A TNFR2 CRP ESR                                                                                                                                                                           

  IFNg, IL-12p70,IL-1β IL-1α IL-17A\          8          8            Wound\        Y          NR           N             N             N             N                       NR         Wound Exudate   [@ref-6]
  IL-6 TNF-α TNF-β IL-16 IL-12/23p40\                                 Exudate                                                                                                                            
  IL-10 IL-4 IL-13 IL-2 IL-15 IL-7 IL-5\                                                                                                                                                                 
  GM-CSF VEGF                                                                                                                                                                                            

  IL-1B IL-6 IL-8 IL-10 IL-17A IL-23\         19         19           Serum only    N          Y\           N             N             N             Y (Adalimumab)          NR         Serum only      [@ref-25]
  TNFR1 TNFR2                                                                                  (Fasting)                                                                                                 

  TNF-α, IL-1B, IL-6 IL-10 IL-17 IL-22\       120        24           Serum and\    Y          N            Y             N             N             Y (Etanercept)          NR         Serum\          [@ref-5]
  IL-1RA                                                              Pus                                                                                                                Pus             

  IL-17 IL-1B IL-10 TNF-α                     44         5            L, PL, U      N          N            N             N             N             N                       NR         Skin            [@ref-31]

  IL-17 Caspase1 NLRP3 S100A8\                22         Yes (NR)     L, PL, U, C   NR         NR           N             N             N             N                       NR         Skin            [@ref-30]
  S100A9                                                                                                                                                                                                 

  TNF-α IL-1β IL-6 IFNg IL-17A IL-22          3          (Unknown)    S             Y          NR           N             N             N             N                       NR         Serum           [@ref-9]

  IL1-2p70 IL-23p19 IL-17                     10         8            L, C          N          NR           N             N             N             Y (ceased 3/25 prior)   NR         Skin            [@ref-32]

  IL-32 IL-32α IL-32β IL-32d IL-32g\          20         10           L, C, S       N          NR           Y             N             N             Y (ceased 8/52 prior)   NR         Skin, Serum     [@ref-29]
  IFNg IL-17 IL-13                                                                                                                                                                                       

  IL-36α IL-36β IL-36g IL-36RA                25         7            L, C, S       N          NR           N             N             N             Y (ceased 3/25 prior)   NR         Skin Serum      [@ref-28]

  TNF-α IFNg IL-1β IL-6 IL-10 IL-19,\         10         16           L             Y          NR           N             N             N             N                       NR         Skin Serum      [@ref-27]
  IL-17A IL-22 IL-36b IL-12/23p40 IL-22\                                                                                                                                                                 
  E Selectin P Selectin CXCL6 CXCL11\                                                                                                                                                                    
  CX3CL1 CCL2 CCL18 CXCL9\                                                                                                                                                                               
  sVEGFR1 MMP2 Cystatin C LCN2                                                                                                                                                                           

  IL-1β IL-2 IL-4 IL-5 IL-6 IL-8 IL-10 IL-\   20         6            L, PL, C      N          NR           Y             N             N             N                       NR         Skin            [@ref-26]
  12p70 TNF-α IFNg                                                                                                                                                                                       

  IL-1α, IL-8                                 10         10           S             N          NR           N             N             N             Y                       NR         Serum           [@ref-33]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"}: Critical Evaluation of Methodology of Studies Included in This Review Key:L= Lesional, PL= Perilesional, U= Uninvolved, C= Control S=Serum, Y=Yes, N=No, NR= Not Reported,

Cytokine analysis
-----------------

A total of 81 discrete cytokines were analysed over the 19 studies (presented in [Table 4](#T4){ref-type="table"}). 6 studies provided a total of 78 outcomes from tissue of lesional or peri-lesional biopsies, 4 studies provided a total of 30 results from serum analysis and 1 study provided 15 results from exudate analysis. The remaining 8 studies did not provide quantification of cytokine levels but did provide analysis of the change and significance between lesion and control samples. The degree of change between lesional and control samples varied widely from 1.5 times the control level (IL-1RA p=0.0112) to 149 times the control level (IL-17 p\<0.05). 33 cytokines were evaluated in more than one study. Only IL-1β, IL-6, IL-8, IL-17A and TNF-α had data from 5 or more separate studies.

###### Reported cytokine results of studies included in this systematic review.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target\         Mean Level\   Mean Level in\      Mean Level in\                                                          Mean Level\                                                              Mean\            Mean Control\                            Fold\                                    Comparison and\                          Comparison and\   \                                   
  Cytokine        in Patient\   Control Serum\      Lesional Tissue\                                                        in\                                                                      Uninvolved\      Tissue\                                  Increase                                 Significance                             Significance      Study\                              
                  Serum\        (pg/mL)             (pg/mL)                                                                 Perilesional\                                                            Tissue\          Levels (pg/mL)                                                                                                                               Reference                           
                  (pg/mL)                                                                                                   Tissue\                                                                  Levels (pg/mL)                                                                                                                                                                                    
                                                                                                                            (pg/mL)                                                                                                                                                                                                                                                                    
  --------------- ------------- ------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------- ----------- ----------- ----------- -----------
  IL-1α                                             1126                                                                                                                                                              2549                                                                              Le:Ce                                    P= 0.53                                   [@ref-6]    

                                0.2                                                                                                                                                                  0.1              NR                                       L:C                                      NS                                                                     [@ref-26]               

  772.0           697.2                                                                                                                                                                                                                                        HSs:Cs                                   NS                                                                     [@ref-33]               

  IL-1RA                                            44.0                                                                                                                                                              29.6                                     1.5                                      L:C                                      P= 0.0112                                 [@ref-26]   

  IL-1β           0.9           0.4                                                                                                                                                                                                                                                                     HSs:Cs                                   P=0.801                                   [@ref-8]    

                                862.5                                                                                                                                                                1503                                                      Le:Ce                                    P= 0.69                                                                [@ref-6]                

                                                                                                                                                                                                                                                               L:C                                      NS                                       Lpa:C             NS          [@ref-25]               

                                SERUM ONLY                                                                                                                                                           HSs:Cs           P= 0.044                                                                                                                   [@ref-5]                                              

                                100                 10                                                                      3                                                                        1                115 fold                                 L:C                                      P= 0.001                                 PL:C              0.05        [@ref-31]               

  L:U             P= 0.01       U:C                 NS                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                      R=0.7 ^[\#](#tfn1){ref-type="other"}^    L:C                                      NS                                                                     [@ref-7]                

                                1.6                                                                                                                                                                  0.0              54.4                                     L:C                                      P= 0.0028                                                              [@ref-26]               

  IL-4                                              6.56                                                                                                                                                              9.77                                                                              Le:Ce                                    P= 0.54                                   [@ref-6]    

                                0.0                                                                                                                                                                  0.1                                                       L:C                                      NS                                                                     [@ref-7]                

  IL-5                                              0.2                                                                                                                                                               0.2                                                                               L:C                                      NS                                        [@ref-7]    

                                30.15                                                                                                                                                                9.314                                                     Le:Ce                                    P= 0.17                                                                [@ref-6]                

  IL-6                                                                                                                                                                                                                                                                                                  L:C [\*](#tfn1){ref-type="other"}\       NS\                                       [@ref-4]    
                                                                                                                                                                                                                                                                                                        L:C [\*\*](#tfn1){ref-type="other"}\     NS\                                                   
                                                                                                                                                                                                                                                                                                        L:C [\*\*\*](#tfn1){ref-type="other"}    NS                                                    

  6.2             0.6                                                                                                                                                                                                                                          HSs:Cs                                   P= 0.001                                                               [@ref-8]                

                                2377                                                                                                                                                                 5451                                                      Le:Ce                                    NS                                                                     [@ref-6]                

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             0.05        [@ref-25]               

                                SERUM ONLY                                                                                  HSs:\                                                                    P= 0.002                                                                                           [@ref-5]                                                                                       
                                                                                                                            Cs ^[+++](#tfn1){ref-type="other"}^                                                                                                                                                                                                                                        

                                124.4                                                                                       101.9                                                                                                                              L:C                                      NS                                                                     [@ref-7]                

  sIL-6R                                            16.3                                                                                                                                                              4.4                                      3.7                                      L:C                                      P= 0.0028                                 [@ref-7]    

  IL-8            NR            NR                  i69.6 / s67.6                                                                                                                                                     64.9                                                                              Li:C                                     P\<0.01           Ls:C        P\<0.001    [@ref-24]   

                                                                                                                                                                                                                                                               L:C [\*](#tfn1){ref-type="other"}\       NS\                                                                    [@ref-4]                
                                                                                                                                                                                                                                                               L:C [\*\*](#tfn1){ref-type="other"}\     NS\                                                                                            
                                                                                                                                                                                                                                                               L:C [\*\*\*](#tfn1){ref-type="other"}    NS                                                                                             

  27.9            36.3                                                                                                                                                                                                                                         HSs:Cs                                   NS                                                                     [@ref-8]                

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             NS          [@ref-25]               

                                1401                                                                                                                                                                 12.0                                                      L:C                                      NS                                                                     [@ref-7]                

  1000            3000                                                                                                                                                                                                                                         L:C                                      P= 0.049                                                               [@ref-33]               

  IL-10                                                                                                                                                                                                                                                                                                 L:C                                      P\<0.05                                   [@ref-4]    

  3.4             3.3                                                                                                                                                                                                                                          HSs:Cs                                   NS                                                                     [@ref-8]                

                                19.85                                                                                                                                                                34.74                                                     Le:Ce                                    NS                                                                     [@ref-6]                

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             0.05        [@ref-25]               

                                SERUM ONLY                                                                                  HSs:Cs ^[+](#tfn1){ref-type="other"}^                                    P= 0.0001                                                                                          [@ref-5]                                                                                       

                                SERUM ONLY                                                                                  HSs:Cs ^[++](#tfn1){ref-type="other"}^                                   P= 0.0001                                                                                          [@ref-5]                                                                                       

                                3.8                 1.1                                                                                                                                              0.4              3-4                                      L:C                                      P= 0.01                                  PL:C              NS          [@ref-31]               

  L:U             P= 0.01       U:C                 NR                                                                                                                                                                                                                                                                                                                                                 

  3               2                                                                                                                                                                                                                                            HSs:Cs                                   NS                                                                     [@ref-27]               

                                19.2                                                                                                                                                                 1.3              14.8                                     L:C                                      P= 0.0028                                                              [@ref-7]                

  IL-11                                             78.6                                                                                                                                                              7.2                                      11.0                                     L:C                                      P= 0.0056                                 [@ref-7]    

  IL-12p40                                          488.3                                                                                                                                                             97.86                                                                             Le:Ce                                    P= 0.07                                   [@ref-6]    

  75              75                                                                                                                                                                                                                                           HSs:Cs                                   NS                                                                     [@ref-27]               

                                0.5                                                                                                                                                                  0.4                                                       L:C                                      NS                                                                     [@ref-7]                

  IL-12p70        3.4           0.6                                                                                                                                                                                                                                                                     HSs:Cs                                   P= 0.427                                  [@ref-8]    

                                9.412                                                                                                                                                                15.02                                                     Le:Ce                                    P= 0.609                                                               [@ref-6]                

                                0.0                                                                                                                                                                  0.0                                                       L:C                                      NS                                                                     [@ref-7]                

  IL-13                                             70.98                                                                                                                                                             55.61                                                                             Le:Ce                                    P= 0.56                                   [@ref-6]    

                                0.0                                                                                                                                                                  0.1                                                       L:C                                      NS                                                                     [@ref-7]                

  IL-15                                             24.5                                                                                                                                                              5.61                                                                              Le:Ce                                    P= 0.18                                   [@ref-6]    

                                1.9                                                                                                                                                                  2.9                                                       L:C                                      NS                                                                     [@ref-7]                

  IL-16                                             15277                                                                                                                                                             15586                                                                             Le:Ce                                    P= 0.97                                   [@ref-6]    

                                22.3                                                                                                                                                                 4.2              5.3                                      L:C                                      P= 0.0028                                                              [@ref-7]                

  IL-17                                                                                                                                                                                                                                                                                                 S:C                                      P\<0.005                                  [@ref-4]    

                                                    SERUM\                                                                                                                                           SERUM ONLY       SERUM\                                                                            HSs:Cs ^[+](#tfn1){ref-type="other"}^    0.014                         [@ref-5]                
                                                    ONLY                                                                                                                                                              ONLY                                                                                                                                                                             

                                                    SERUM\                                                                                                                                           SERUM ONLY       SERUM\                                                                            HSs:Cs ^[++](#tfn1){ref-type="other"}^   0.005                         [@ref-5]                
                                                    ONLY                                                                                                                                                              ONLY                                                                                                                                                                             

                                150                 45                                                                      1                                                                        1                149 fold                                 L:C                                      P= 0.05                                  PL:C              0.05        [@ref-31]               

  L:PL            NS            U:C                 0.05                                                                                                                                                                                                                                                                                                                                               

                                                                                                                            No Quantification                                                        L:C              ↑(NS)                                    L:PL                                     No Diff                                  [@ref-30]                                             

                                                                                                                                                                                                                      R=0.66 ^[\#](#tfn1){ref-type="other"}^                                            NS                                                                     [@ref-27]               

  IL-17A                                                                                                                                                                                                                                                                                                L:C                                      P\<0.005                                  [@ref-4]    

  5.6             0.3                                                                                                                                                                                                                                          HSs:Cs                                   NS                                                                     [@ref-8]                

                                1006                                                                                                                                                                 32.7                                                      Le:Ce                                    NS                                                                     [@ref-6]                

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             NS          [@ref-25]               

  4               5                                                                                                                                                                                                                                            HSs:Cs                                   NS                                                                     [@ref-27]               

                                8.1                 NR                                                                                                                                               1.1              7.3                                      L:C                                      P= 0.0056                                                              [@ref-26]               

  IL-22                                                                                                                                                                                                                                                                                                 L:C                                      NS                                        [@ref-4]    

  8.8             0.0                                                                                                                                                                                                                                          HSs:Cs                                   NS                                                                     [@ref-8]                

  IL-23                                                                                                                                                                                                                                                                                                 L:C                                      NS                Lpa:C       0.05        [@ref-25]   

                                                                                                                                                                                                                                                               R=0.68 ^[\#](#tfn1){ref-type="other"}^                                            NS                                        [@ref-7]    

  IL-32           50ng/mL       1ng/mL              Only Normalised Values Provided                                                                                                                  4 (skin)\        L:C                                      P= 0.01                                  HSs:\                                    p\<0.05           [@ref-29]                           
                                                                                                                                                                                                     50\                                                                                                Cs                                                                                             
                                                                                                                                                                                                     (serum)                                                                                                                                                                                           

  IL-32α                                                                                                                                                                                                                                                       3 fold                                   L:C                                      P= 0.01                                   [@ref-28]   

  IL-32β                                                                                                                                                                                                                                                       2 fold                                   L:C                                      P= 0.05                                   [@ref-29]   

  IL-32g                                                                                                                                                                                                                                                       Not\                                     L:C                                      P= 0.001                                  [@ref-29]   
                                                                                                                                                                                                                                                               elevated                                                                                                                                

  IL-32d                                                                                                                                                                                                                                                       3 fold                                   L:C                                      NS                                        [@ref-29]   

  IL-36α                                            0.4                                                                     0.02                                                                                      0.02                                                                              L:C                                      P=0.0174          PL:C        NS          [@ref-3]    

  250             0                                                                                                                                                                                  1                45.07 fold                               L:C                                      P= 0.01                                                                [@ref-28]               

  IL-36b                                            4.33                                                                    3.00                                                                                      0.51                                                                              L:C                                      P= 0.0001         PL:C        0.0035      [@ref-3]    

  15              4                                                                                                                                                                                  1                1.45 fold                                L:C                                      P= 0.25                                                                [@ref-28]               

  IL-36g                                            3.64                                                                    0.83                                                                                      0.49                                                                              L:C                                      P= 0.0161         PL:L        0.0302      [@ref-3]    

  100             20                                                                                                                                                                                 1                1.96 fold                                L:C                                      P= 0.07                                                                [@ref-28]               

  IL-36RA                                           0.46                                                                    0.28                                                                                      0.06                                                                              L:C                                      P= 0.0001         PL:C        0.0003      [@ref-3]    

  50              100           No Quantificaiton                                                                           No\                                                                      L:C              P= 0.10                                                                                                                    [@ref-28]                                             
                                                                                                                            Increase                                                                                                                                                                                                                                                                   

  IL-37                                             3.24                                                                    14.7                                                                                      1.81                                                                              PL:L                                     P= 0.0002         PL:C        0.0001      [@ref-3]    

  IL-38                                             0.09                                                                    0.19                                                                                      0.06                                                                              L:C                                      P= 0.0230         PL:C        0.0069      [@ref-3]    

  TNF-α                                             i69.4                                                                   66.6 [s](#tfn1){ref-type="other"}                                        NR                                                        65.8                                     NR                                       Li:C              NS          Ls:C        NS          [@ref-24]

                                                                                                                                                                                                                                                               L:C [\*](#tfn1){ref-type="other"}\       NS\                                                                    [@ref-4]                
                                                                                                                                                                                                                                                               L:C [\*\*](#tfn1){ref-type="other"}\     NS\                                                                                            
                                                                                                                                                                                                                                                               L:C [\*\*\*](#tfn1){ref-type="other"}    NS                                                                                             

                                                    83.26                                                                                                                                                             65.74                                    Le:Ce                                    P= 0.7                                                                 [@ref-6]                

                                SERUM ONLY          SERUM\                                                                                                                                                                                                     HSs:Cs ^[+](#tfn1){ref-type="other"}^    P=0.021                                                                [@ref-5]                
                                                    ONLY                                                                                                                                                                                                                                                                                                                                               

                                2.2                 1.3                                                                     0.6                                                                      0.7                                                       L:C                                      P=0.01                                   PL:C              0.01        [@ref-31]               

  L:PL            NS            U:C                 NS                                                                                                                                                                                                                                                                                                                                                 

                                0.3                                                                                                                                                                  0.2              1.6                                      L:C                                      P=0.0336                                                               [@ref-26]               

  TNF-β                                             9.24                                                                                                                                                              1.65                                                                              Le:Ce                                    P=0.03                                    [@ref-6]    

                                0.4                                                                                                                                                                  0.4              NR                                       L:C                                      NS                                                                     [@ref-26]               

  sTNFR1          879.8         325.9                                                                                                                                                                                                                                                                   HSs:Cs                                   P \<0.001                                 [@ref-8]    

                                                                                                                                                                                                                                                               L:C                                      NS                                       Lpa:C             0.05        [@ref-25]               

                                78.0                                                                                                                                                                 40.2             1.9                                      L:C                                      P= 0.0112                                                              [@ref-26]               

  sTNFR2          927.9         527.4                                                                                                                                                                                                                                                                   HSs:Cs                                   P= 0.053                                  [@ref-8]    

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             0.05        [@ref-25]               

                                47.0                                                                                                                                                                 8.1              5.8                                      L:C                                      P= 0.0028                                                              [@ref-26]               

  hBD1                                              0.019\                                                                                                                                                            0.058\                                   0.3\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.240\                                 [@ref-4]    
                                                    0.021\                                                                                                                                                            0.077\                                   0.3\                                     L:C [\*\*](#tfn1){ref-type="other"}\     P= 0.132\                                             
                                                    0.018                                                                                                                                                             0.095                                    0.2                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.026                                              

  hBD2                                              0.013\                                                                                                                                                            0.011\                                   1.1\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.937\                                 [@ref-4]    
                                                    0.019\                                                                                                                                                            0.018\                                   1.1\                                     \>L:C [\*\*](#tfn1){ref-type="other"}\   P= 0.699\                                             
                                                    0.058                                                                                                                                                             0.067                                    0.9                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.937                                              

  hBD3                                              76.9 [i](#tfn1){ref-type="other"}                                       75.7 [s](#tfn1){ref-type="other"}                                                                                                  72.5                                     NR                                       Li:C              P\<0.05     Ls:C        NS          [@ref-24]

                                0.33\                                                                                                                                                                0.117\           2.8\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.485\                                                              [@ref-4]                
                                0.33\                                                                                                                                                                0.125\           2.6\                                     L:C [\*\*](#tfn1){ref-type="other"}\     P= 0.394\                                                                                      
                                0.379                                                                                                                                                                0.203            1.9                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.485                                                                                       

  S100A7                                            i84.8                                                                   77.8 [s](#tfn1){ref-type="other"}                                                                                                  71.5                                     NR                                       Li:C              P\<0.001    Ls:C        P\<0.05     [@ref-24]

                                1.516\                                                                                                                                                               0.177\           8.6\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.009\                                                              [@ref-4]                
                                1.625\                                                                                                                                                               0.354\           4.6\                                     L:C [\*\*](#tfn1){ref-type="other"}\     P= 0.180\                                                                                      
                                2.297                                                                                                                                                                0.707            3.2                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.132                                                                                       

  S100A8                                            24.251\                                                                                                                                                           4.925\                                   4.9\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.240\                                 [@ref-4]    
                                                    25.992\                                                                                                                                                           11.314\                                  2.3\                                     L:C [\*\*](#tfn1){ref-type="other"}\     P= 0.537\                                             
                                                    24.251                                                                                                                                                            10.556                                   2.3                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.393                                              

                                                                                                                                                                                                                      NR                                       L:C                                      ↑ (NS)                                   L:PL              ↑ (NS)      [@ref-30]               

  S100A9                                            0.003\                                                                                                                                                            0.002\                                   1.7\                                     L:C [\*](#tfn1){ref-type="other"}\       NS\                                       [@ref-4]    
                                                    0.005\                                                                                                                                                            0.004\                                   1.1\                                     L:C [\*\*](#tfn1){ref-type="other"}\     NS\                                                   
                                                    0.003                                                                                                                                                             0.006                                    0.6                                      L:C [\*\*\*](#tfn1){ref-type="other"}    NS                                                    

                                                                                                                                                                                                                                                               L:C                                      ↑ (NS)                                   L:PL              ↑ (NS)      [@ref-30]               

  LL37                                              84.1 [i](#tfn1){ref-type="other"} /80.9 [s](#tfn1){ref-type="other"}                                                                                              75.8                                                                              Li:C                                     P\<0.05           Ls:C        NS          [@ref-24]   

  Lyzozyme                                          55.2 [i](#tfn1){ref-type="other"} / 52.7 [s](#tfn1){ref-type="other"}                                                                                             59.6                                                                              Li:C                                     NS                Ls:C        P\<0.05     [@ref-24]   

  MIF                                               77.8 [i](#tfn1){ref-type="other"}/ 77.8 [s](#tfn1){ref-type="other"}                                                                                              70.7                                                                              Li:C                                     NS                Ls:C        P\<0.01     [@ref-24]   

  αMSH                                              NR                                                                      i74.6 [i](#tfn1){ref-type="other"} / 73.1 [s](#tfn1){ref-type="other"}                    NR                                       70.9                                     Li:C                                     P\<0.01           Ls:C        P\<0.01     [@ref-24]   

  MHC1                                              75.5 [i](#tfn1){ref-type="other"}/74.7 [s](#tfn1){ref-type="other"}                                                                                               74.4                                                                              Li:C                                     NS                Ls:C        NS          [@ref-24]   

  RNase7                                            0.435\                                                                                                                                                            0.063\                                   7.0\                                     L:C [\*](#tfn1){ref-type="other"}\       P= 0.145\                                 [@ref-4]    
                                                    0.330\                                                                                                                                                            0.077\                                   4.3\                                     L:C [\*\*](#tfn1){ref-type="other"}\     P= 0.589\                                             
                                                    0.574                                                                                                                                                             0.109                                    5.3                                      L:C [\*\*\*](#tfn1){ref-type="other"}    P= 0.179                                              

  IP10                                              \                                                                                                                                                                 \                                                                                 L:C [\*](#tfn1){ref-type="other"}\       P\<0.05\                                  [@ref-4]    
                                                    89.9                                                                                                                                                              12.6                                                                              L:C [\*\*](#tfn1){ref-type="other"}\     P\<0.005\                                             
                                                                                                                                                                                                                                                                                                        L:C [\*\*\*](#tfn1){ref-type="other"}    P\<0.05                                               

  CCL3                                              0.4                                                                                                                                                               0.2                                      2.0                                      L:C                                      P= 0.0196                                 [@ref-26]   

  CCL5                                              \-\                                                                                                                                                               \-\                                                                               L:C [\*](#tfn1){ref-type="other"}\       P\<0.05\                                  [@ref-4]    
                                                    46.1\                                                                                                                                                             6.2\                                                                              L:C [\*\*](#tfn1){ref-type="other"}\     P\<0.05\                                              
                                                    -                                                                                                                                                                 -                                                                                 L:C [\*\*\*](#tfn1){ref-type="other"}    NS                                                    

                                7.6                                                                                                                                                                  1.4              5.4                                      L:C                                      P= 0.0112                                                              [@ref-26]               

  CCL20                                                                                                                                                                                                                                                                                                 L:C                                      P\<0.005                                  [@ref-4]    

  CCL27                                                                                                                                                                                                                                                                                                 L:C                                      P\<0.05                                   [@ref-4]    

  CRP             13.4          1.2                                                                                                                                                                                                                                                                     HSs:Cs                                   p\<0.001                                  [@ref-8]    

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             0.05        [@ref-25]               

  ESR             29.5          10.2                                                                                                                                                                                                                                                                    HSs:Cs                                   \<0.001                                   [@ref-8]    

                                                                                                                                                                                                                                                               L:C                                      P= 0.05                                  Lpa:C             0.05        [@ref-25]               

  IFNg                                                                                                                                                                                                                                                         R=0.7                                    L:C                                      NS                                        [@ref-7]    

                                                                                                                                                                                                                      \<5%\                                    HSs:Cs                                   ↑ (NS)                                                                 [@ref-9]                
                                                                                                                                                                                                                      Normal                                                                                                                                                                           

                                1418                                                                                                                                                                 102.5                                                     Le:Ce                                    P= 0.027                                                               [@ref-6]                

                                                                                                                                                                                                                                                               HSs:Cs                                   P\<0.05                                  L:C               P\<0.05     [@ref-4]                

  GMCSF                                             78.45                                                                                                                                                             82.13                                                                             Le:Ce                                    P= 0.96                                   [@ref-6]    

                                0.4                                                                                                                                                                  0.0              NR                                       L:C                                      NS                                                                     [@ref-26]               

  VEGF                                              632.1                                                                                                                                                             1544                                                                              Le:Ce                                    P= 0.23                                   [@ref-6]    

  sVEGFR1         60            60                                                                                                                                                                                                                                                                      HSs:Cs                                   NS                                        [@ref-27]   

  Caspase 1                                                                                                                                                                                                           No Quanti                                No Quanti                                L:C                                      ↑ (NS)            L:PL        ↑ (NS)      [@ref-30]   

  NLRP3                                                                                                                                                                                                               No Quanti                                No Quanti                                L:C                                      ↑ (NS)            L:PL        NS          [@ref-30]   

  CAMP                                                                                                                                                                                                                                                         4                                        L:C                                      NS                                        [@ref-7]    

  Uteroglobulin   20            20                                                                                                                                                                                                                                                                      HSs:Cs                                   NS                                        [@ref-27]   

  Cystatin C      0.85          0.8                                                                                                                                                                                                                                                                     HSs:Cs                                                                             [@ref-27]   

  LCN2            90            40                  0.5                                                                                                                                              0.02                                                                                               HSs:Cs                                   \<0.001           L:C         \<0.001     [@ref-27]   

  BD2             0.9           1                                                                                                                                                                                                                                                                       HSs:Cs                                   NS                                        [@ref-27]   

  MMP2            200           210                                                                                                                                                                                                                                                                     HSs:Cs                                   \<0.05                                    [@ref-27]   

  BLC                                               8.1                                                                                                                                                               0.58                                     10.5                                     L:C                                      P= 0.0056                                 [@ref-26]   

  ICAM-1                                            98.7                                                                                                                                                              31.9                                     3.1                                      L:C                                      P= 0.0028                                 [@ref-26]   

  Eotaxin                                           0.1                                                                                                                                                               0.1                                      NR                                       L:C                                      NS                                        [@ref-26]   

  Eotaxin2                                          3.9                                                                                                                                                               2.5                                      NR                                       L:C                                      NS                                        [@ref-26]   

  CXCL6           160           140                                                                                                                                                                                                                                                                                                              NS                                        [@ref-27]   

  CXCL9                                             219.8                                                                                                                                                             13.8                                     16                                       L:C                                      P= 0.0028                                 [@ref-26]   

  CXCL11          0.4           0.4                                                                                                                                                                                                                                                                                                              NS                                        [@ref-27]   

  CX3CL1          0.9           1                                                                                                                                                                                                                                                                                                                NS                                        [@ref-27]   

  I-309                                             0.4                                                                                                                                                               0.3                                      NR                                       L:C                                      NS                                        [@ref-26]   

  MCP1                                              47.5                                                                                                                                                              37.1                                     NR                                       L:C                                      NS                                        [@ref-26]   

  M-CSF                                             0.4                                                                                                                                                               0.2                                      NR                                       L:C                                      NS                                        [@ref-26]   

  MIP1b                                             16.1                                                                                                                                                              5.8                                      NR                                       L:C                                      NS                                        [@ref-26]   

  MIP1d                                             0.1                                                                                                                                                               0.1                                      NR                                       L:C                                      NS                                        [@ref-26]   

  PDGF                                              0.5                                                                                                                                                               0.2                                      NR                                       L:C                                      NS                                        [@ref-26]   

  TIMP1                                             260.1                                                                                                                                                             166.2                                    NR                                       L:C                                      NS                                        [@ref-26]   

  TIMP2                                             989.2                                                                                                                                                             997.3                                    NR                                       L:C                                      NS                                        [@ref-26]   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key: L= Lesional ; PL= Perilesional; C= Control; NS= Not Significant ; HSs= HS Serum; Cs= Control Serum; HSe= HS Exudate; Ce= Control Exudate; I = Inflamed lesional skin, S= Scarred lesional skin, \#= Vs CAMP, \*= NT (Non-Treated) Samples ,\*\* = Stimulation by Pam2CSK4 Lipopeptide,\*\*\* Stimulation by Muramyl Dipeptide (MDP), + Heat Killed Candida Albicans; ++ Heat Killed Staph Aureus, +++ Lipopolysaccharide;

Cytokines and inflammatory proteins which were elevated in more than one study in lesional tissue included IL-1β, IL-6R, IL-10, IL-17A, IL-36α, IL-36β, IL-36 **γ**, IL-36RA, TNF-α, sTNFR2, hBD1, hBD2, hBD3, s100A7, LL37/Cathelicidin, CCL3, CCL5, CCL27 and BLC. Cytokines and inflammatory proteins elevated in peri-lesional tissue included IL-1β, IL-17, IL-36β, IL-36RA, IL-37, IL-38 and TNF-α. IL-37 was the only cytokine identified which showed significant differences between lesional and peri-lesional tissue, with a 1.81 times elevation in lesional compared to peri-lesional tissue (p=0.0002) ^[@ref-3]^. IL-17 was elevated in unaffected HS tissue compared to control patient tissue (p\<0.05) in one study ^[@ref-31]^. In HS tissue, S100A9, hBD1 and hBD2 were reduced but this data did not meet statistical significance. Two studies measuring IL-1β levels showed no statistically significant difference between lesional and control skin ^[@ref-7],\ [@ref-25]^. No significant elevation of IL-6 was seen in lesional tissue compared to control with the exception of 1 study ^[@ref-25]^. IL-8 levels only just made significance in two studies ^[@ref-5],\ [@ref-7]^, with one study showing significant elevation of IL-8 in lesional compared to control tissue ^[@ref-24]^. Two additional studies showed no significant difference ^[@ref-4],\ [@ref-8]^. TNF-α levels were significantly elevated compared to control tissue in two studies ^[@ref-7],\ [@ref-31]^ but not significantly in 2 additional studies ^[@ref-4],\ [@ref-24]^. sTNFR1 was significantly elevated in one study ^[@ref-26]^ whilst showing a non-significant difference in a second study ^[@ref-25]^. CCL5 was significant in 2 studies in lesional tissue compared with controls ^[@ref-4],\ [@ref-26]^. One methodology using muramyl dipeptide (MDP) did not reach statistical significance compared to stimulation with Pam2CSK4 Lipopeptide, and non-treated (NT) cells. IFN- **γ** was elevated in lesional tissue with no significance in one study ^[@ref-28]^ and significance in another ^[@ref-4]^.

Elevated cytokines and inflammatory proteins in HS serum included IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-17, TNF-α, sTNFR1, CRP, ESR, LC2, and MMP2. TNF-β, and IFN-γ were elevated in wound exudate from active HS lesions. IFN-γ was noted to be decreased in HS patient serum compared to healthy control serum, despite the elevation in wound exudate. Conflicting results were seen in serum findings in IL-10, IL-17 and IFN-γ. One study demonstrated elevated serum IL-10 levels compared to control ^[@ref-5]^ whereas two other studies ^[@ref-8],\ [@ref-27]^ showed no significant difference. Whilst two studies ^[@ref-4],\ [@ref-5]^ illustrated elevated IL-17 Serum levels in HS patients, one study ^[@ref-7]^ showed no significant difference between patients and controls. IFN-γ showed no statistically significant decrease in the serum of HS patients compared to control in one study ^[@ref-9]^ but a significant difference in a larger, higher powered study ^[@ref-4]^.

Because adalimumab improves HS through TNF antagonism ^[@ref-1],\ [@ref-2]^, this cytokine must be classified as pathogenic. TNF mediates inflammation in a classic "sepsis" cascade in tissues---in this pathway LPS from gram negative bacteria activates TNF release from cells, and then TNF stimulates production of IL-1b, IL-6, and IL-8, leading to neutrophil attraction into sites of infection ^[@ref-2],\ [@ref-4]^. Increases in IL-1β and IL-8 measured in HS, as well as neutrophil accumulation, could result from this pathway. Alternatively, in psoriasis, TNF is a major cytokine that acts on the IL-23/Type 17 T-cell pathway at two points. First TNF induces IL-23 synthesis in myeloid (CD11c+) dendritic cells in the skin ^[@ref-34]^. Second, TNF (as well as other cytokines that also activate NF-kB) act synergistically with IL-17A or IL-17F to increase synthesis of many other cytokines, chemokines, and inflammatory molecules in keratinocytes and other cell types. There are several clues that an IL-23/Type17 T-cell pathway may be active in HS which include detection of T ~h~17 T-cells in skin infiltrates, increased production of IL-17A, and increased production of LL-37/cathlecidin, S100A7, S100A8, S100A9, LCN2, IL-8, beta-defensins and IL-36; which are all molecules induced by IL-17 in keratinocytes, as also the presence of psoriasis-like epidermal hyperplasia in some reports. The increased production of CCL20 ^[@ref-4]^, would be predicted to increase tissue infiltration of both T ~h~17 T-cells and CD11c+ DCs, which have both been observed in HS, and increased production of TGF-β could increase differentiation of T ~h~17 T-cells from precursors and/or influence scarring in skin lesions. If IL-17 is driving inflammation in HS, one would expect to see increased production of additional chemokines that regulate neutrophil chemoattraction (CXCL1, CXCL2, CXCL3). Epidermal hyperplasia is not presently explained in HS, but this could be related potentially to increased expression of IL-19, IL-20 or IL-22, which are associated with the IL-23/Type 17 T-cell axis. If IL-22 is produced in HS lesions, this would implicate T ~h~22 T-cells as a T-cell type also associated with the IL-23/Type 17 T-cell axis. There is an uncertain role for other T-cell subsets in HS. Increased production of CXCL9 and IP-10 (CXCL10) are often linked to production of IFN-γ from T ~h~1 T-cells in inflammatory sites, but IL-26 or IL-29, which are also cytokines produced by T ~h~17 T-cells are alternative activators of STAT1 and CXCL9 production. IL-32 production in HS may also be linked to a T-cell subset that produces this cytokine. Low production of T ~h~2 associated cytokines (IL-4, IL-5, or IL-13) has been measured in HS, suggesting an unlikely role of this T-cell subset. Likewise, the presence and function of T regulatory cells (Tregs) in HS lesions needs further study. IL-10 which is elevated in HS could be produced by either Tregs or the cDC1 (BDCA3+) DC subset, but levels may be inadequate to control tissue inflammation. At present, dendritic cell subsets are also incompletely characterized in HS. Potential sources of IL-12 or IL-23 are CD11c+ DCs, which includes the tissue resident BDCA-1+ (cDC2) subset and less mature inflammatory DCs, which are abundant cells in inflammatory lesions of psoriasis or atopic dermatitis but have not been investigated in HS. Cytokine contributions by other cell types such as innate lymphoid cells, macrophages, mast cells, and other leukocytes also remains to be determined.

Cytokine analysis methods
-------------------------

The methodologies of cytokine analysis varied widely ( [Table 5](#T5){ref-type="table"}). 92 results were produced using electrochemical luminescence (ECL) procedures from three separate systems and manufacturers. 62 results were produced using ELISA. 18 results ^[@ref-4]^ were performed with either ELISA or ECL but not further specified. 15 results were produced using polymerase chain reaction (PCR) with three separate systems from three manufacturers. Four discrete cytokines (IL-10, IL-17, TNF-α and IFN-γ) were analysed using all three techniques (ECL, ELISA and PCR), whilst 15 discrete cytokines (IL-6, IL-8, IL12p40, IL-17A, IL-22, IL-23, S100A7, S100A8, S100A9, RNAse7, IP-10, CCL5, CCL20, CCL27) were analysed using ELISA and ECL only. We note IL-17 levels may well be below the lower limit of quantification with ELC and ELISA based approaches, with only the Singulex platform having the ability to quantify levels of IL-17 present in blood and serum of normal subjects.

###### Cytokine analysis methodology of studies included in this review.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytokine     Method    Details                                                                                                                                                   Study
  ------------ --------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  IL-1α        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  IL-1ra       ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  IL-1β        ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               PCR       IL10, IL17A, IL1Β, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler\              [@ref-31]
                         (Roche, Pleasanton, CA, U.S.A.)                                                                                                                           

               PCR       (Hs01555410_m1), ABI-Prism 7300 Sequence Detector System (Applied Biosystems                                                                              [@ref-7]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  IL-4         ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-5         ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

  IL-6         ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA). The Milliplex MAP multiplex assay                                                                 [@ref-25]

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  sIL-6R       ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-8         ELISA     pABG AHC0881 1:50 rabbit antihuman                                                                                                                        [@ref-24]

               ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-33]

  IL-10        ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               PCR       IL10, IL17A, IL1Β, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler\              [@ref-31]
                         (Roche, Pleasanton, CA, U.S.A.)                                                                                                                           

               ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-11        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-12p40     ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-12p70     ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-13        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-15        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-16        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-7]

  IL-17        ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               PCR       IL10, IL17A, IL1Β, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler\              [@ref-31]
                         (Roche, Pleasanton, CA, U.S.A.)                                                                                                                           

               PCR       IL-17 (clone AF-317-NA; R&D Systems, Wiesbaden, Germany),                                                                                                 [@ref-30]

               PCR       IL-17 (Hs00174383_m1), ABI-Prism 7300 Sequence Detector System                                                                                            [@ref-27]

  IL-17A       ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA). eBioscience, Paris, France                                                   [@ref-4]
               ECL                                                                                                                                                                 

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  IL-22        ELISA     ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA). eBioscience, Paris, France                                                   [@ref-4]

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

  IL-23        ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               PCR       (Hs00992441_m1) ABI-Prism 7300 Sequence Detector System (Applied Biosystems                                                                               [@ref-7]

  IL-32        PCR       IL-32 (Hs00992441_m1), ABI-Prism 7300 Sequence Detector System                                                                                            [@ref-29]

  IL-32α       PCR       IL-32a (Hs04353657_gH), ABI-Prism 7300 Sequence Detector System                                                                                           [@ref-29]

  IL-32β       PCR       IL-32b (Hs04353658_gH), ABI-Prism 7300 Sequence Detector System                                                                                           [@ref-29]

  IL-32g       PCR       IL-32c (Hs04353656_g1), ABI-Prism 7300 Sequence Detector System                                                                                           [@ref-29]

  IL-32d       PCR       IL-32d (Hs04353659_gH), ABI-Prism 7300 Sequence Detector System                                                                                           [@ref-29]

  IL-36α       ELISA     Rabbit polyclonal anti-IL-36a (C-terminal; ab180909), from Abcam, Cambridge, U.K. at 1 : 500 dilution.                                                    [@ref-3]

               ELISA     IL-36a AF1078, RnD                                                                                                                                        [@ref-28]

  IL-36β       ELISA     Rabbit polyclonal anti- IL-36b (C-terminal; ab180890) from Abcam, Cambridge, U.K. at 1 : 500 dilution.                                                    [@ref-3]

               ELISA     AF1099, RnD                                                                                                                                               [@ref-28]

  IL-36g       ELISA     Mouse monoclonal anti-IL-36c ab156783; (Abcam, Cambridge, U.K.) at 1 : 500 dilution.                                                                      [@ref-3]

               ELISA     AF2320, RnD                                                                                                                                               [@ref-28]

  IL-36RA      ELISA     Rabbit polyclonal from Abcam, Cambridge, U.K. at 1 : 500 dilution.                                                                                        [@ref-3]

               ELISA     AF1275, RnD                                                                                                                                               [@ref-28]

  IL-37        ELISA     Rabbit polyclonal Abcam, Cambridge, U.K. at 1 : 500 dilution.                                                                                             [@ref-3]

  IL-38        ELISA     Rabbit polyclonal Abcam, Cambridge, U.K. at 1 : 500 dilution.                                                                                             [@ref-3]

  TNF-α        ELISA     TNF-alpha: 559071 mABG 1:10 mouse antihuman                                                                                                               [@ref-24]

               ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ELISA     Cytokines were measured in duplicate by ELISA (R&D Minneap- olis, USA).                                                                                   [@ref-5]

               PCR       Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler                                                                                [@ref-31]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  TNF-β        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  sTNFR1       ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  sTNFR2       ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-8]

               ECL       xMAP technology (Luminex Corporation, Austin, TX, USA)                                                                                                    [@ref-25]

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  hBD1         ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  hBD2         ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  hBD3         ELISA     ELISA 1 : 400; rabbit antihuman                                                                                                                           [@ref-24]

               ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  S100A7       ELISA     Psoriasin HL15-4 mAbG 1:20,000 mouse antihuman                                                                                                            [@ref-24]

               ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  S100A8       ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ELISA     S100A8 and S100A9 (monospecific affinity-purified rabbit antisera to S100A8 and to S100A9                                                                 [@ref-30]

  S100A9       ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ELISA     S100A8 and S100A9 (monospecific affinity-purified rabbit antisera to S100A8 and to S100A9                                                                 [@ref-30]

  LL37         ELISA     Cathelicidin ab64892 pAbG 1:1000 rabbit antihuman                                                                                                         [@ref-24]

  Lyzozyme     ELISA     Lysozyme A0099 pAbG 1:100 rabbit antihuman                                                                                                                [@ref-24]

  MIF          ELISA     MIF MAB289 mABG 1:100 mouse antihuman                                                                                                                     [@ref-24]

  αMSH         ELISA     alpha MSH M09393 mABG 1:500 rabbit antihuman                                                                                                              [@ref-24]

  MHC1         ELISA     MHC1 W6/32 mABG 1:50 mouse antihuman                                                                                                                      [@ref-24]

  RNase7       ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  IP10         ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  CCL3         ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  CCL5         ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

               ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  CCL20        ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  CCL27        ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  CRP          ECL       xMAP luminex Luminex Corporation, Austin, TX, USA                                                                                                         [@ref-8]

               ECL       xMAP luminex Luminex Corporation, Austin, TX, USA                                                                                                         [@ref-25]

  ESR          ECL       xMAP luminex Luminex Corporation, Austin, TX, USA                                                                                                         [@ref-8]

               ECL       xMAP luminex Luminex Corporation, Austin, TX, USA                                                                                                         [@ref-25]

  IFNg         PCR       (Hs00174143_m1), ABI-Prism 7300 Sequence Detector System (Applied Biosystems)                                                                             [@ref-7]

               ELISA     ELISA kits from Sanquin (Amsterdam, The Nether- lands)                                                                                                    [@ref-9]

               ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ELISA/\   ELISA (Quantikine; R&D Systems) or Luminex assay (Millipore, Billerica, MA).                                                                              [@ref-4]
               ECL                                                                                                                                                                 

  GMCSF        ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

               ELISA     Quantibody Human Inflammation array 3 (RayBiotech Inc., Norcross, GA, U.S.A.).                                                                            [@ref-26]

  VEGF         ECL       Meso Scale Discovery electrochemiluminescent assay (MSD, Meso Scale Diagnostics, Rockville, MD MSD V-Plex cytokine panel 1 and the V-plex\                [@ref-6]
                         proinflammatory panel 1                                                                                                                                   

  sVEGFR1      ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  Caspase 1    ELISA     Kelly *et al.* Caspase-1 fluorochrome inhibitor of caspases (FLICA) (ImmunoChemistry Technologies, Bloomington, MN, U.S.A.                                [@ref-30]

  NLRP3        PCR       Kelly IL10, IL17A, IL1 **Β**, IL18 and NLRP3 was performed with predesigned Taqman gene expression assays (Applied Biosystems) on a Roche Light Cycler\   [@ref-30]
                         (Pleasanton, CA, U.S.A.)                                                                                                                                  

  CAMP         PCR       (Hs00189038_m1) ABI-Prism 7300 Sequence Detector System (Applied Biosystems)                                                                              [@ref-7]

  Uteroglob    ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  Cystatin C   ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  LCN2         ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  BD2          ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  MMP2         ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  BLC          ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  ICAM-1       ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  Eotaxin      ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  Eotaxin2     ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  CXCL6        ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  CXCL9        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  CXCL11       ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  CX3CL1       ELISA     Quantikine enzyme-linked immunosorbent assay (ELISA) systems from Bio-Techne                                                                              [@ref-27]

  I-309        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  MCP1         ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  M-CSF        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  MIP1b        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  MIP1d        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  PDGF-BB      ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  TIMP1        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]

  TIMP2        ECL       (CBA Human Inflammation kit and CBA Human TH1⁄TH2 Cytokine kit; BD Biosciences, Franklin Lakes, NJ, U.S.A.) Analyssi: FACSCalibur (BD Biosciences)        [@ref-26]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 4](#T4){ref-type="table"}: Antibodies Used for Identification of Cytokines in Studies Included in this Systematic Review. ECL: Electrochemicoluminescence

Assessment of bias
------------------

Assessment of bias is presented in [Table 6](#T6){ref-type="table"}. Two of the 14 questions regarding participation rate and loss to follow up were considered not applicable. All included studies identified clear objectives and a clearly defined study population. No clear inclusion or exclusion criteria were specified for 17 of the 19 studies. Power estimation was made for one study ^[@ref-33]^, and recording of all exposures (disease activity, comorbidities etc) were made prior to assessment of the outcomes (cytokine levels). The timeframe of analysis was sufficient to identify an association, but only 10 of the 19 studies (52.6%) documented different levels of exposures (disease severity, metabolic comorbidities, family history etc). There were no serial measures of cytokine levels in the majority of studies. Only three studies ^[@ref-5],\ [@ref-25],\ [@ref-33]^, examining cytokine levels after monoclonal antibody administration has measurements at two distinct time points. Outcomes of interest (cytokine levels) were measured consistently within studies, however there was great variance in the methods of measurement and analysis between studies ( [Table 5](#T5){ref-type="table"}). No studies took into account known confounding variables into analysis of their results by stratification or regression analyses.

###### Risk of bias across studies included in this review.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\                       1\. Was\     2\. Was\      3\. Was the\     . Were all\      5\. Was a\        6\. For the\    7\. Was the\     8\. For\      9\. Were the\    10\. Was the\   11\. Were the\     12 Were the\    13\. Was\   14\. Were key\
  Reference                    the\         the study\    participation\   the subjects\    sample size\      analyses in\    timeframe\       exposures\    exposure\        exposure(s)\    outcome\           outcome\        loss to\    potential\
                               research\    population\   rate of\         selected or\     justification,\   this paper,\    sufficient\      that can\     measures\        assessed\       measures\          assessors\      follow-\    confounding\
                               question\    clearly\      eligible\        recruited\       power\            were the\       so that\         vary in\      (independent\    more than\      (dependent\        blinded to\     up after\   variables\
                               or\          specified\    persons at\      from the\        description,\     exposure(s)\    one could\       amount or\    variables)\      once over\      variables)\        the exposure\   baseline\   measured\
                               objective\   and\          least 50%?       same or\         or variance\      of interest\    reasonably\      level, did\   clearly\         time?           clearly\           status of\      20% or\     and adjusted\
                               in this\     defined?                       similar\         and effect\       measured\       expect\          the study\    defined,\                        defined, valid,\   participants?   less?       statistically\
                               paper\                                      populations\     estimates\        prior to the\   to see an\       examine\      valid,\                          reliable, and\                                 for their\
                               clearly\                                    (including\      provided?         outcome(s)\     association\     different\    reliable, and\                   implemented\                                   impact\
                               stated?                                     the same\                          being\          between\         levels\       implemented\                     consistently\                                  on the\
                                                                           time period)?\                     measured?       exposure\        of the\       consistently\                    across\                                        relationship\
                                                                           Were\                                              and outcome\     exposure\     across\                          all study\                                     between\
                                                                           inclusion and\                                     if it existed?   as related\   all study\                       participants?                                  exposure(s)\
                                                                           exclusion\                                                          to the\       participants?                                                                   and\
                                                                           criteria for\                                                       outcome\                                                                                      outcome(s)?
                                                                           being in\                                                           (e.g.,\                                                                                       
                                                                           the study\                                                          categories\                                                                                   
                                                                           prespecified\                                                       of\                                                                                           
                                                                           and applied\                                                        exposure,\                                                                                    
                                                                           uniformly\                                                          or\                                                                                           
                                                                           to all\                                                             exposure\                                                                                     
                                                                           participants?                                                       measured\                                                                                     
                                                                                                                                               as\                                                                                           
                                                                                                                                               continuous\                                                                                   
                                                                                                                                               variable)?                                                                                    
  ---------------------------- ------------ ------------- ---------------- ---------------- ----------------- --------------- ---------------- ------------- ---------------- --------------- ------------------ --------------- ----------- ----------------
  Moran\                       Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-2]^                                                                                                                                                                                                                        

  Emelianov\                   Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-24]^                                                                                                                                                                                                                       

  Hessam\                      Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-3]^                                                                                                                                                                                                                        

  Hotz *et al.* ^[@ref-4]^     Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N

  Thomi\                       Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-7]^                                                                                                                                                                                                                        

  Jimenez-\                    Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  Gallo\                                                                                                                                                                                                                                     
  *et al.* ^[@ref-8]^                                                                                                                                                                                                                        

  Banerjee\                    Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-6]^                                                                                                                                                                                                                        

  Jimenez-\                    Y            Y             N/A              Y                N                 Y               Y                N             Y                N               Y                  NR              N/A         N
  Gallo\                                                                                                                                                                                                                                     
  *et al.* ^[@ref-25]^                                                                                                                                                                                                                       

  Kanni *et al.* ^[@ref-5]^    Y            Y             N/A              N                N                 Y               Y                Y             Y                Y               Y                  NR              N/A         N

  Kelly *et al.* ^[@ref-31]^   Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N

  Lima *et al.* ^[@ref-30]^    Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N

  Ten Oever\                   Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-9]^                                                                                                                                                                                                                        

  Schlapbach\                  Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-32]^                                                                                                                                                                                                                       

  Thomi\                       Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-29]^                                                                                                                                                                                                                       

  Thomi\                       Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-28]^                                                                                                                                                                                                                       

  Wolk *et al.* ^[@ref-27]^    Y            Y             N/A              N                N                 Y               Y                N             Y                N               Y                  NR              N/A         N

  Van der Zee\                 Y            Y             N/A              N                N                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-26]^                                                                                                                                                                                                                       

  Kanni\                       Y            Y             N/A              Y                Y                 Y               Y                Y             Y                N               Y                  NR              N/A         N
  *et al.* ^[@ref-33]^                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key: Y = Yes; N= No, NR= Not Reported N/A = Not Applicable

Assessment of heterogeneity
---------------------------

36 of the 81 identified cytokines or inflammatory proteins were assessed by more than 1 study. 23 of those cytokines had raw data available. No studies had sufficient measures of spread in order to calculate I ^2^measure of heterogeneity and so chi-squared statistic was used as an alternate marker of heterogeneity ( [Table 7](#T7){ref-type="table"}) along with a funnel plot ( [Figure 3](#f3){ref-type="fig"}). In total, 18 individual cytokines (78.2%) were found to demonstrate heterogeneity. Only eight cytokines (Serum IL-10, Lesional IL-1α, IL-12p70, hBD1, hBD2, hBD3, S100A9 and GMCSF) illustrated homogeneity. Due to this high level of heterogeneity and concerns regarding the methodological quality of included studies, meta-analysis was not deemed appropriate to perform.

###### Table of heterogeneity of cytokine studies by chi-squared tests for homogeneity.

  Cytokine               Chi Squared   P
  ---------------------- ------------- ----------------
  **IL1a Lesional**      **0.3525**    **p=0.552705**
  IL1b Lesional          153.5947      p\<0.00001
  IL4 Lesional           4.3992        P=0.035955
  IL5 Lesional           15.1692       P=0.000098
  IL6 Lesional           461.9724      P\<0.00001
  IL8 Lesion             846.6251      P\<0.0001
  IL8 Serum              94.4212       P\<0.0001
  IL10 Lesion            90.3211       P\<0.0001
  **IL10 Serum**         **0.1595**    **P=0.689624**
  IL12p40 Lesional       4.9618        P=0.025913
  **IL12p70 Lesional**   **2.2116**    **P=0.136973**
  IL13 Lesional          5.4163        P=0.019949
  IL15 Lesional          39.2837       P\<0.00001
  IL16 Lesional          126.1959      P\<0.00001
  IL17A Lesional         22.6668       P\<0.00001
  IL17A Serum            19.1621       P=0.000012
  TNFa Lesional          6.9761        P=0.030561
  TNFb Lesional          7.4004        P=0.006521
  **hBD1 Lesional**      **2.3317**    **P=0.311656**
  **hBD2 Lesional**      **0.6488**    **P=0.722954**
  **hBD3 Lesional**      **1.0314**    **P=0.597084**
  S100A7 Lesional        621.2537      P\<0.00001
  S100A8 Lesional        19.6371       P=0.000054
  **S100A9 Lesional**    **1.27**      **P=0.529927**
  RNAse 7                6.7263        P=0.034626
  **GMCSF Lesional**     **1.9405**    **P=0.163611**

Discussion
==========

The overall quality of reporting in the identified studies was low with little consistency between methodologies and cytokines examined. There was also great variability in the ages, genders, comorbidities, associated conditions and treatments of the patients included in these studies. This was again reflected in the high number of cytokines with statistical heterogeneity ( [Table 7](#T7){ref-type="table"}). The studies presenting conflicting data are often those studies with lower numbers of patients as well as lack of matched controls and/or lack of stratification by treatment. Meta-analysis using individual patient data would be required in order to account for these factors and re-assess the relationship between lesional and control cytokine levels.

In assessing the relationship between lesional and peri-lesional tissue, it has been demonstrated by many authors that different cytokines are present in peri-lesional tissue as opposed to lesional tissue. The definition of peri-lesional tissue is fairly consistent in the studies examined being 2cm from an active HS nodule on unaffected skin. However, no studies reported ultrasound examination of the peri-lesional skin to ensure that subclinical extension of the adjacent nodule (either in the dermis or the subcutaneous tissue) was being inadvertently sampled. This is an important differentiation to make in terms of identifying the subclinical pathogenic processes that precipitate this disease.

The raw data collated illustrates a number of paradoxically elevated levels of control cytokines (IL-15, IL-16) ( [Table 4](#T4){ref-type="table"}). Many of these control readings lie near the lower detection limit of specific assays in individual papers, and thus the possibility of erroneously elevated control readings cannot be excluded. The wide interquartile ranges of studies which did report individual patient data ^[@ref-7]^, suggest that analyzing aggregate data is not optimal and is prone to misrepresentation of the relationship between clinical disease, comorbidities and cytokine levels. Furthermore, high levels of heterogeneity within the measurements of individual cytokines suggest that examination of and correction for other variables or confounders is required.

Methodological quality
----------------------

Regarding methods of cytokine analysis, a number of authors have identified variability in cytokine levels measured with different forms of multiplex assays as well as traditional ELISA methods ^[@ref-35]--\ [@ref-39]^. Different methods of cytokine analysis are known to be prone to variability, with some cytokines more sensitive than others. For example, IFN- **γ** and IL-1β were overestimated compared with ELISA methods ^[@ref-37]^, whilst IL-6 levels were underestimated ^[@ref-37]^. IL-6 levels when compared across four different multiplex assays showed significant variation in detectable range, accuracy and responsiveness ^[@ref-36]^. The correlation of TNF-α between ELISA and Multiplex assays was also poor (r=0.31) ^[@ref-36]^. Issues also exist with minimum detectable levels of cytokines with specific bead-based arrays ^[@ref-36]^ As an example, minimal detectable dose readings reported for IL-12p70 using some multiplex arrays ^[@ref-39]^ are higher than the levels reported in lesional HS samples ^[@ref-6]^. Therefore, whilst the general trends in the level of consistently elevated or suppressed cytokines in HS are reliable, the quantification of individual cytokines as well as the relationship between comorbidities and cytokine levels requires further research with consistent, reliable and accurate methodologies in order to further dissect the inflammatory cascade in this disease.

Keratinocyte mediated inflammatory pathways
-------------------------------------------

The majority of elevated cytokines and inflammatory proteins identified in lesional skin of HS (TNF-α, IL-1β, IL-6, IL-8, IL-11, IL-23, IL-17A, IL-33, IL-36, LL-37, S100A7, S100A8, S100A9, GM-CSF, TGF-β, hBD2, hBD3, CCL3, CXCL9, CXCL11, PDGF, CCL5, CCL-20, MIF, GM-CSF and LCN2) are those known to be produced by keratinocytes, as well as perpetuating a self-amplification pathway ^[@ref-34]^ ( [Figure 2](#f2){ref-type="fig"}). Additionally T-cells produce IL-17A, IL-17F, IL-26, IL-29, and IFN-γ; dendritic cells produce IL-12, IL-23 and possibly IL-39; neutrophils produce S100A8 and S100A9 (calgranulin); and innate lymphoid cells also contribute IFN-γ, IL-17A and IL-17F. This inflammatory model has been well documented and explored in both psoriasis and atopic dermatitis ^[@ref-34],\ [@ref-40]^. The psoriasiform epidermal hyperplasia seen in HS (mediated by IL-17 and maintained by IL-23-mediated T ~h~17 stimulation) ^[@ref-34]^ reflects this common inflammatory pathway.

![Inflammatory pathways in hidradenitis suppurativa, a schematic representation of the results identified in this systematic review.\
Immunological 'priming' occurs due to the contribution of adipose tissue, genetic susceptibility, smoking-related inflammatory mediators and obesity related pro-inflammatory signals and the composition of the microbiome. Increased activity of cDC1, cDC2 and T cells lead to both keratinocyte hyperplasia via the actions of IL-12 and IL-23, as well as a Th17 predominant immune response. Alterations of antimicrobial peptides (AMP's) also occur throughout the epidermis. The dermal inflammation interacting with the hyperplastic epidermis result leads to a self-perpetuating inflammatory feed forward mechanism mediated by IL-36, Il-1B and TNF-a. The development of scarring and sinus tracts is associated with MMP2, ICAM-1 and TGF-Beta, with possible augmentation of ICAM-1 and TGF-B signaling via specific components of the microbiome. TNF-a, PGE2 and CXCL2 then lead to additional feed forward mechanisms perpetuating the inflammatory cycle.](f1000research-7-18879-g0001){#f2}

![Funnel plot of selected cytokine in lesional and control samples of hidradenitis suppurativa.\
IL-1a = Red, IL-10 = Blue, IL-12p70 = Green, hBD1 = Purple, hBD2 = light purple, hBD3 = Black, S100A9 = White, GMCSF = Yellow.](f1000research-7-18879-g0002){#f3}

The other elevated non-keratinocyte produced cytokines in HS (IL-4, IL-5, IL-10, IL-16, IL-17A, IL-22, IL-32, IL-36, hBD1), are produced by a combination of dendritic cells, monocytes, neutrophils and CD4+ T cells. IL-4 and IL-5 as key cytokines in the T ~h~2 axis are consistent with the findings of Mast cells in HS ^[@ref-41]^, as well as the pruritus, which is frequently reported by patients. IL-10 in HS is produced by Treg cells ^[@ref-2]^ (although dendritic cells may also be a source), and whilst quantitatively the IL-10 signal appears paradoxically elevated, it can be explained by the up-regulation of T cells including Treg cells, which although significantly elevated from baseline, are not elevated enough in comparison to T ~H~17/IL-17/IL-22 signal to counteract this strong pro-inflammatory cascade ^[@ref-2]^. Further exploration of these cytokines may reveal the initial trigger(s) of the inflammatory cascade in HS, or correlations with known pro-inflammatory comorbidities.

Insights into pathogenesis of HS
--------------------------------

In light of investigations in psoriasis and atopic dermatitis, the role of dendritic cells in HS needs to be clarified, as dendritic cell influx has been reported in histological studies ^[@ref-41],\ [@ref-42]^, and they may contribute to the high IL-10 and IL-15 levels reported. IL-32 is a second cytokine produced by dendritic cells, but has only been reported in one study ^[@ref-29]^. Further research into the functional role of IL-32 in the activity of dendritic cells in HS would be of value. The role of IL-20, IL-22, IL-24 and IL-26 needs further clarification. IL-19, TSLP and CCL17 (TARC) have not yet been examined in HS and this is required in order to further explore the role of dendritic cell, monocyte and T cell activation and migration in this disease.

It is well established that smoking, obesity and diabetes are strongly associated with HS ^[@ref-13]--\ [@ref-19],\ [@ref-42],\ [@ref-43]^. The immunological effects of smoking include increase in number and responsiveness of dendritic cells, altered function of Treg cells and activation of Th17 pathways ^[@ref-44]^, whilst obesity and diabetes can result in production of IL-1β, IL-6 and TNF-α through activated macrophages in adipose tissue ^[@ref-45],\ [@ref-46]^. These potential mechanistic pathways (which may prime or contribute towards inflammation in HS) require validation in functional studies. However, if they are a significant contributor to inflammation, the presence or absence of these comorbidities need to be considered in future cytokine studies as confounding variables in order to identify significant biochemical markers independent of these other pro-inflammatory states that reflect the pathogenesis of HS.

The role of the microbiome ^[@ref-42],\ [@ref-43]^ in stimulating chronic inflammation has parallels in diabetes ^[@ref-47]^ and colonic inflammation ^[@ref-48]^ and the presence of *Porphyromonas* and *Peptoniphilus* species has been associated with a subpopulation of patients with HS ^[@ref-42]^. *Porphyromonas* has been associated with systemic inflammation and atherosclerosis through aberrant toll-like-receptor 4 signalling ^[@ref-48]^ and is not part of the natural cutaneous flora ^[@ref-43]^. Altered cutaneous and gastrointestinal microbiome can also act via microbiome metabolites (including lipopolysaccharides, short chain fatty acids and bile salts) ^[@ref-49]^ through stimulation of myeloid dendritic cells via G Protein Coupled Receptors (including GPR41, GPR43 and GPR109A) ^[@ref-49],\ [@ref-50]^. The microbiome may be implicated as a trigger factor for the initial inflammatory cascade in HS in a proportion of patients. Similarly, the presence of genetic polymorphisms as reported in HS ^[@ref-51]^ have the potential to up-regulate inflammatory activity through shedding of IL-6R, IL-15R, TNF-α ^[@ref-52]^ as well as up-regulating the response of dendritic cells to LPS stimulation via ADAM17 (which has been demonstrated to be elevated in a published gene expression study of HS) ^[@ref-53]^. These pathways may be involved prior to the activation of keratinocyte-mediated inflammation, and hence, may reveal novel targets for new interventions to control the disease prior to the onset of destructive inflammation.

Limitations, interpretation and generalisability
------------------------------------------------

The limitations to this study include the high degree of methodological variability ( [Table 5](#T5){ref-type="table"}) and high impact of bias ( [Table 6](#T6){ref-type="table"}) within the included studies. The lack of individual patient data has also prevented any further analysis into the contribution of comorbidities such as smoking and obesity to variable levels of cytokines in lesional tissue and/or serum. This, along with the high level of heterogeneity in many cytokines ( [Table 7](#T7){ref-type="table"}), has resulted in analyses of the collated data being limited to descriptive analyses only and limited the generalisability of results.

Conclusions
===========

Through this review we have catalogued the various cytokines that have been reported as elevated in lesional, peri-lesional tissue, serum or exudate of HS patients. We have also identified those cytokines with inconsistent results and identified methodological factors that may explain variability in findings. We have identified a number of missing links in disease pathogenesis with respect to cytokine actions and pathways that must be addressed in future work. Areas for further investigation include the role of dendritic cells in HS, the contribution of obesity, smoking, diabetes and the microbiome to cytokine profiles in HS, and examining the natural history of the disease through longitudinal measurements of cytokines over time.

Data availability
=================

All data underlying the results are available as part of the article and no additional source data are required.

Extended data
-------------

OSF: Extend data. Data Collection Sheet Cytokine. Review HS. [https://doi.org/10.17605/OSF.IO/N2E7A](https://dx.doi.org/10.17605/OSF.IO/N2E7A) ^[@ref-22]^

License: [CC0 1.0 Universal](https://creativecommons.org/publicdomain/zero/1.0/)

Reporting guidelines
--------------------

OSF: PRISMA checklist for 'A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa'. [https://doi.org/10.17605/OSF.IO/N2E7A](https://dx.doi.org/10.17605/OSF.IO/N2E7A) ^[@ref-22]^

License: [CC0 1.0 Universal](https://creativecommons.org/publicdomain/zero/1.0/)
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This is a long time needed review trying to shed light in the pathogenesis of hidradenitis suppurativa (HS). My concerns are coming from the biggest hurdle the authors had to overcome from the very beginning of their attempt i.e. the great heterogeneity of the existing evidence. Due to this, I find over-exaggerated the conducted approach to set-up a mechanistic interpretation for the disease. I believe that the heterogeneity is so vast that it is almost impossible to suggest the pathways implicated in the pathogenesis of HS. To this end, I suggest that the mechanistic parts are omitted and Figure 2 as well.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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This very instructive study aims at analyzing previous cytokine studies in HS patients, in skin tissue, blood, serum and exudates, to assess relevancy and reliability of these studies.

The authors have performed an extensive work, methods seem perfectly appropriate. The authors are very critical and rigorous in their approach, looking for confounding factors, which is highly desired.

The authors could also mention that genetic heterogeneity may play a role in the diversity of results and encourage using similar phenotypes for future studies.

This analysis brings up a very important and honest contribution to the current knowledge in cytokines involved in HS and therefore deserves indexing.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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Thank you for the opportunity to review this manuscript and congratulations to the authors for their great efforts in putting this systematic review together. Research on the role of cytokines in HS is important, as it may lead to new targets for therapy and a better understanding of the pathophysiology of HS.

**[Summary]{.ul}**

This systematic review focused on collecting all data published on cytokine studies in tissue, blood, serum and exudate in hidradenitis suppurativa. 81 discrete cytokines were examined in HS patients (n=564) and control patients (n=198) in 19 studies. Methodology varied greatly among studies, which were generally of low quality. When measuring levels of cytokines, substantial variance was found and the majority of cytokines showed heterogeneity. IL-17 signalling appeared to be a significant component. Suggestions for further research were discussed.

**[Questions]{.ul}**

**Are the rationale for, and objectives of, the Systematic Review clearly stated?**

Yes.

**Are sufficient details of the methods and analysis provided to allow replication by others?**

Yes. However, I wonder why the term 'hidradenitis suppurativa' is not in the search strategy and 'hidradenitidis suppurative' is? 'Hidradenitidis' is not an existing word, as far as I know and will not provide any search results. Please adjust.

**Is the statistical analysis and its interpretation appropriate?**

Yes, as far as I can judge as a non-statistician. The analyses used are ones I have little experience with myself. I'll refrain from commenting on this section.

**Are the conclusions drawn adequately supported by the results presented in the review?**

Partly. The last conclusion 'examining the natural history of the disease through longitudinal measurements of cytokines over time' is not discussed anywhere else in this article. First, I suggest changing 'history' to 'course'. Moreover, I am wondering, how the authors propose to do this. Monitoring the natural course of the disease, would mean patients cannot receive any treatment for their HS, during this proposed study. Depending on how long the natural course is meant to be monitored, I don't think it is ethical to withhold patients from treatment.

Please elaborate on this conclusion with a specific proposal or otherwise rephrase or maybe leave out this conclusion.

**[Other comments]{.ul}**

Page 9 last paragraph/Page 28 -- 1 ^st^ paragraph: You state that 'psoriasiform epidermal hyperplasia is seen in HS'. Please provide a reference for this statement. The reference provided only references to the pathway likely responsible for this in psoriasis.

Page 28 -- 4 ^th^ paragraph: 'These potential mechanistic pathways (which may prime or contribute towards inflammation in HS) require validation in functional studies.' Could you please provide an example on how such a functional study should be designed to produce reliable results?

Table 4: the abbreviation 'Lpa' is not clarified in the key section of the table. Does 'Le' (page 11, IL-1a, first row) mean lesion exudate? 

Table 6: the number four of question four is missing in the top row of the table on both pages (24-25). Please insert.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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